KEYNOTE-671 trial

Keytruda + Chemo Boosts Survival in Resectable NSCLC (ESMO 2023)

KEYNOTE-671 Trial: Keytruda Sets New Standards in the Perioperative Treatment Landscape (ESMO 2023)

Anika Sharma

ESMO 2023: LBA56 Neoadjuvant NSCLC is a challenging market with few treatment options and many unmet needs. Merck’s Keytruda is ...